- Assay duration:Multiple steps
- Assay Type:Sandwich
- Conjugate ELISA:Biotin
- Format:Pre-coated
- Host:Rabbit
- Primary antibody reactivity:Human
- Target protein:LOX1
- Size:1 kit
- Sample Type:Serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- Cross Reactivity:No significant cross-reactivity or interference between Lectin Like Oxidized Low Density Lipoprotein Receptor 1 (LOX1) and analogues was observed
- Detection Method:Colorimetric
- Time to Results:3 h
- Shelf Life:12 Months
- Detection Range:0.156 - 10 ng/ml
- Storage Temperature:4 °C for one month (frequent use), −20 °C for one year
- Sample Volume:100 µl
- Sensitivity:0.060 ng/ml
- Regulatory Status:RUO
- Cat. No.:MSPP-SEB859HU
- No. of tests:96 wells
This assay has high sensitivity and excellent specificity for detecting Human LOX1 (Lectin Like Oxidized Low Density Lipoprotein Receptor 1). The assay range is from 0.156 to 10 ng/ml (Sandwich kit) with a sensitivity of 0.060 ng/ml. There is no detectable cross-reactivity with other relevant proteins. Activity loss rate and accelerated stability test ect have been conducted to guarantee the best performance of the products after long storage and delivery.
- High sensitivity and specificity
- Perfect reproducibility and consistency across batches
- Quality control with three-level inspections
- Wide range of targets/species available
- Intra-assay: CV<10%; Inter-assay: CV<12%
Oxidized low-density lipoprotein receptor 1 is a protein that in humans is encoded by the OLR1 gene. This gene encodes a receptor protein which belongs to the C-type lectin superfamily. This gene is regulated through the cyclic AMP signaling pathway. The encoded protein binds, internalizes and degrades oxidized low-density lipoprotein. This protein may be involved in the regulation of Fas-induced apoptosis. This protein may play a role as a scavenger receptor. Mutations of this gene have been associated with atherosclerosis, risk of myocardial infarction, and may modify the risk of Alzheimer's disease. Alternative transcript variants have been described but their full-length sequence has not been determined. Berberine inhibits ORL1 (LOX-1)with the improvement in hemoglobin A1c and AGEs in diabetics.